MaxCyte, Inc. (AIM:MXCT)

Market Cap	338.29M
Revenue (ttm)	34.02M
Net Income (ttm)	-26.66M
Shares Out	105.71M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,050
Average Volume	20,563
Open	310.11
Previous Close	320.00
Day's Range	310.00 - 320.00
52-Week Range	259.14 - 410.00
Beta	1.19
RSI	32.49
Earnings Date	Mar 11, 2025

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engin...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 143
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: MXCT

Financial Performance

In 2023, MaxCyte's revenue was $41.29 million, a decrease of -6.72% compared to the previous year's $44.26 million. Losses were -$37.92 million, 60.9% more than in 2022.

Financial numbers in USD